Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomly allocated to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF after 3 years

被引：0
|
作者：
Daar, Eric [1 ]
Orkin, Chloe [2 ]
Sax, Paul [3 ]
Koenig, Ellen [4 ]
Clarke, Amanda [5 ]
Baumgarten, Axel [6 ]
Brinson, Cynthia [7 ]
Huang, Hailin [8 ]
Martin, Hal [8 ]
机构：
[1] Harbor UCLA Med Ctr, Lundquist Inst, Torrance, CA 90509 USA
[2] Queen Mary Univ London, London, England
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Inst Dominicano Estudios Virolg, Santo Domingo, Dominican Rep
[5] Univ Hosp Sussex NHS Fdn, Brighton, E Sussex, England
[6] Zibp uBAG GbR, Berlin, Germany
[7] Cent Hlth, Austin, TX USA
[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2022年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
O16
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF
    Pozniak, A.
    Maggiolo, F.
    Podzamczer, D.
    Yazdanpanah, Y.
    Gupta, S.
    Esser, S.
    Mounzer, K.
    Grossberg, R.
    Post, F.
    Huang, H.
    Acosta, R.
    Baeten, J.
    Hindman, J.
    Martin, H.
    Orkin, C.
    [J]. HIV MEDICINE, 2021, 22 : 125 - 125
  • [2] B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results
    Podzamczer, D.
    Stellbrink, H-J
    Orkin, C.
    Pozniak, A.
    Arribas, J.
    Koenig, E.
    Ramgopal, M.
    Baumgarten, A.
    Wei, X.
    SenGupta, D.
    Martin, H.
    [J]. HIV MEDICINE, 2019, 20 : 18 - 18
  • [3] Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF
    Orkin, C.
    Antinori, A.
    Rockstroh, J.
    Guillen, S. Moreno
    Martorell, C.
    Molina, J.
    Lazzarin, A.
    Maggiolo, F.
    Yazdanpanah, Y.
    Andreatta, K.
    Huang, H.
    Hindman, J.
    Martin, H.
    Baeten, J.
    Pozniak, A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 88 - 89
  • [4] Patient-reported outcomes among adults living with HIV-1 who were randomly allocated to B/F/TAF versus DTG/ABC/3TC in two Phase 3 controlled clinical trials over 48 weeks
    Wohl, D.
    Clarke, A.
    Maggiolo, F.
    Garner, W.
    Martin, H.
    [J]. HIV MEDICINE, 2019, 20 : 63 - 63
  • [5] Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo
    Acosta, T. Parraga
    Osborn, Z.
    Lee, J. C.
    Haubrich, R. H.
    McNicholl, I.
    McKinnon, J. E.
    [J]. HIV MEDICINE, 2019, 20 : 88 - 88
  • [6] A Phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at Week 48
    Gallant, J.
    Lazzarin, A.
    Mills, A.
    Orkin, C.
    Podzamczer, D.
    Tebas, P.
    Girard, P-M
    Brar, I.
    Daar, E.
    Wohl, D.
    Rockstroh, J.
    Wei, X.
    White, K.
    Martin, H.
    Quirk, E.
    Cheng, A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 103 - 104
  • [7] B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 count in two Phase III randomized, controlled clinical trials: Week 96 results
    Podzamczer, D.
    Stellbrink, H.
    Orkin, C.
    Pozniak, A.
    Arribas, J.
    Koenig, E.
    Ramgopal, M.
    Baumgarten, A.
    Wei, X.
    Cheng, A.
    SenGupta, D.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [8] A Phase 3, randomised, controlled clinical trial of bictegravir in a fixed-dose combination, B/F/TAF, versus ABC/DTG/3TC in treatment-naive adults at week 96
    Waters, L.
    Wohl, D.
    Yazdanpanah, Y.
    Baumgarten, A.
    Clarke, A.
    Hagins, D.
    Ramgopal, M.
    Wei, X.
    White, K.
    Collins, S.
    Martin, H.
    [J]. HIV MEDICINE, 2019, 20 : 16 - 16
  • [9] Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) plus F/TAF in treatment-naive HIV-1 positive adults: Week 96
    Stellbrink, H.
    Arribas, J.
    Stephens, J.
    Albrecht, H.
    Sax, P.
    Maggiolo, F.
    Creticos, C.
    Martorell, C.
    Wei, X.
    White, K.
    Collins, S.
    Cheng, A.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [10] Real-world persistence of E/C/F/TAF versus DTG+ABC/3TC regimens for treatment of HIV in a large Spanish cohort: VACH
    Teira, R.
    Romero, A.
    Roca, B.
    Munoz-Sanchez, M.
    Sepulveda, M.
    Puig, T.
    Espinosa, N.
    Merino, M.
    Geijo, P.
    Castano, M.
    Estrada, V.
    Ribera, E.
    Domingo, P.
    De la Fuente, B.
    Montero, M.
    Galindo, M.
    Peraire, J.
    Martinez, E.
    Lozano, F.
    Terron, A.
    Garcia, J.
    Deig, E.
    Munoz-Sanz, A.
    Gutierrez, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
12345